Struggling with underwhelming sales of its debut commercial drug Monjuvi, MorphoSys has unveiled a new licensing deal with HIBio on two pipeline candidates which will help it focus on its key assets.
Monjuvi (tafasitamab-cxix) was launched by MorpoSys and partners Incyte as a second-line therapy for diffuse large B-cell lymphoma nearly two years ago, but has failed to live up to expectations, thanks to a mid-pandemic launch and strong competitors such as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
